Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 91 to 100 of 123 total matches.
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
.
Women of childbearing potential should use effective
contraception before starting treatment, during ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
Evinacumab (Evkeeza) for Homozygous Familial Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
a pregnancy test before starting evinacumab
and should use contraception during treatment and
for at least 5 ...
The FDA has approved evinacumab-dgnb (Evkeeza –
Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor,
for adjunctive IV treatment of homozygous familial
hypercholesterolemia (HoFH) in patients ≥12 years
old. Evinacumab is the first ANGPTL3 inhibitor to be
approved in the US.
Ripretinib (Qinlock) for GIST (online only)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
and their
male partners should use effective contraception
during treatment with ripretinib and for 1 week after ...
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
% of premenopausal women
and is commonly caused by uterine fibroids.2
Combination contraceptives ...
Oriahnn (Abbvie), a fixed-dose combination of the
gonadotropin-releasing hormone (GnRH) receptor
antagonist elagolix, the estrogen estradiol, and the
progestin norethindrone acetate copackaged with
elagolix alone, has been approved by the FDA for oral
treatment of heavy menstrual bleeding associated
with uterine leiomyomas (fibroids) in premenopausal
women. It is the first product to be approved in the
US for this indication. Elagolix (Orilissa) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis. The
GnRH receptor antagonist...
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
effective
contraception while taking alemtuzumab and for
4 months after stopping it. Because of its large ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
pup weight,
and increased mortality. An effective form of
contraception is recommended during ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
in animal studies; women of childbearing age should use effective contraception while taking ivabradine ...
View the Comparison Table: Some Drugs for HFrEF
Twirla - A New Contraceptive Patch
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
Twirla - A New Contraceptive Patch ...
The FDA has approved Twirla (Agile Therapeutics),
a transdermal contraceptive patch containing the
estrogen ethinyl estradiol and the progestin
levonorgestrel, for use in women with a BMI <30 kg/m2.
It is the second contraceptive patch to become
available in the US; Xulane, a patch that delivers
ethinyl estradiol and the progestin norelgestromin,
has been available since 2014.
Pitolisant (Wakix) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
CYP3A4 substrates, such as
oral contraceptives. Women should use nonhormonal
contraceptive methods ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Avapritinib (Ayvakit) for GIST
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
of reproductive potential and their male
partners should use effective contraception during
treatment ...
The FDA has approved the oral tyrosine kinase
inhibitor avapritinib (Ayvakit – Blueprint Medicines)
for treatment of unresectable or metastatic gastrointestinal
stromal tumors (GISTs) harboring a
platelet-derived growth factor receptor alpha
(PDGFRA) D842V or other PDGFRA exon 18 mutation.
Avapritinib is the first drug to be approved for this
indication in the US.